Neurocrine biosciences presents new ingrezza® (valbenazine) capsules data demonstrating early and sustained improvements in chorea associated with huntington's disease

Data presented at the 2023 mds international congress of parkinson's disease and movement disorders® san diego , aug. 28, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced new data on now fda-approved ingrezza® (valbenazine) capsules for the treatment of adults with chorea associated with huntington's disease (hd), including exploratory results from the phase 3 kinect®-hd study, which showed consistently greater improvements in hd chorea with ingrezza versus placebo from week 2 to week 12. these data will be presented at the mds international congress of parkinson's disease and movement disorders® august 27-31 in copenhagen, denmark.
NBIX Ratings Summary
NBIX Quant Ranking